A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
IGF Binding Protein-2 (IGFBP-2)
Test CodeCPT Codes
83519
Preferred Specimen
Patient Preparation
Fasting is preferred
Minimum Volume
Transport Temperature
Specimen Stability
Refrigerated: 4 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Methodology
Radioimmunoassay (RIA)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Report Available
Clinical Significance
This test measures serum concentration of insulin-like growth factor binding protein 2 (IGFBP-2). The value of testing IGFBP-2 has been researched for various disorders, including obesity, type 2 diabetes, cancer, and Alzheimer disease [1,2].
IGFBP-2 belongs to the IGFBP family of 6 proteins that bind and transport insulin-like growth factors (IGFs) and regulate IGF bioavailability. IGFBP-2 is present in very high concentrations during fetal development, progressively falling after birth. Among the 6 IGFBPs, IGFBP-2 has been involved in the IGF activity in most organs, and its role, either dependent or independent of IGFs, has been implicated in bone growth, metabolism, and malignancy [1].
The clinical application of IGFPB-2 measurement was explored in numerous studies but has not been well-established. IGFBP-2 is the most abundantly expressed IGFBPs in several cancers, such as glioma, prostate, breast, and ovarian cancers, possibly contributing to the aggressiveness of these cancers [1]. Low levels of IGFBP-2 are associated with obesity, type 2 diabetes mellitus, and metabolic syndrome [1]. The therapeutic potential of IGFPB-2 has been investigated preclinically in increasing insulin sensitivity, decreasing adipogenesis, and inhibiting tumor growth and metastasis.
Additionally, IGFBP-2 levels were correlated with cognitive outcomes, possibly by inhibiting the neuroprotective effects of IGFs in the brain. Cognitively healthy adults with elevated levels of IGFBP-2 may have higher risk to develop all-cause dementia and Alzheimer disease dementia [2]. Therefore, IGFBP-2 has been suggested as a potential risk predictor and therapeutic candidate for dementia [2].
The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.
References
1. Yau SW, et al. J Cell Commun Signal. 2015;9(2):125-142.
2. McGrath ER, et al. Ann Clin Transl Neurol. 2019;6(9):1659-1670.